Structural perspective on the design of selective DYRK1B inhibitors
P Grygier, K Pustelny, F Menezes… - bioRxiv, 2022 - biorxiv.org
DYRK1B, has been recently recognized as a critical therapeutic target in oncology,
metabolic syndrome, and non-alcoholic fatty liver disease. However, the development of …
metabolic syndrome, and non-alcoholic fatty liver disease. However, the development of …
[PDF][PDF] Structural perspective on the design of selective DYRK1B inhibitors
P Grygier, K Pustelny, G Dubin, A Czarna - scholar.archive.org
DYRK1B kinase recently emerged as a potential target in cancer, metabolic syndrome, and
nonalcoholic fatty liver disease, but the lack of structural information hinders the design of …
nonalcoholic fatty liver disease, but the lack of structural information hinders the design of …
Structural perspective on the design of selective DYRK1B inhibitors
P Grygier, K Pustelny, G Dubin, A Czarna - bioRxiv, 2022 - biorxiv.org
DYRK1B kinase recently emerged as a potential target in cancer, metabolic syndrome, and
nonalcoholic fatty liver disease, but the lack of structural information hinders the design of …
nonalcoholic fatty liver disease, but the lack of structural information hinders the design of …
Structural perspective on the design of selective DYRK1B inhibitors
P Grygier, K Pustelny, G Dubin, A Czarna - 2022 - europepmc.org
DYRK1B kinase recently emerged as a potential target in cancer, metabolic syndrome, and
nonalcoholic fatty liver disease, but the lack of structural information hinders the design of …
nonalcoholic fatty liver disease, but the lack of structural information hinders the design of …